RE:RE:RocheCollaboration and Partnering are certainly not distincly different, as shown in the text at the end of the pipeline slide. Oncolytics uses the two words interchangeably, you can see this from simply looiking at the heading and their first sentence! Throw the text into chatgbt and even one of the most advance AI's will tell you that based on ONC's usage of the terms the differences are slight and ambiguous.
But yes, I can see where a big pharma would "collaborate" with a microcap biotech to run a pre-clinical or P! or very small P2 trial. The big pharma would provide their product and some guidance through the course of these collaborations but not necessarily funds.
However, there is no way that a big pharma would simply "collaborate" with a microcap biotech to run a critical phase 3 trial. THEY WOULD BE A PARTNER, and there would be significant cooperation between the two companies and the big pharma would provide both product and funding.
I mantiain that MC is being deceptive (as is their practice) when the present Roche as a "collaborator" for their supposedly pending panc phase 3.